Cancer Clinical Investigation

Icahn School Of Medicine At Mount Sinai, New York NY

Investigators

Linked publications & trials

Abstract

The Cancer Clinical Investigation (CCI) program was introduced as a new program in the TCI 2019 CCSG renewal application, with a primary focus centered around treatment science. It brings together a group of 49 investigators with complementary and synergistic expertise and is the key hub for translation of insights emerging from Cancer Immunology (CI), Cancer Mechanisms (CM), Cancer Prevention & Control (CPC), Community Outreach and Engagement (COE) and CCI wet or dry laboratory settings to the clinic. CCI provides clinical expertise, startup funds for investigator-initiated trials, drug development consultation, and platforms for interdisciplinary collaboration which are critical for bench-to-bedside translation. The CCI program is co-led by experts Dr. Jian Jin, PhD (drug discovery, medicinal chemistry), Dr. Samir Parekh, MD (hematological malignancies), and Dr. Matthew Galsky, MD (solid tumors, and clinical-translational research). CCI members leading the Early Phase Therapeutics Unit (EPTU) help execute early phase clinical trials. Several unique CCI features including Clinical Trial Incubators, Drug Discovery Clinics and Tumor Working Groups that interface with other programs for initiating IITs and multi-PI grants. CCI program members were awarded more than $9M in peer reviewed funding including 27 multi-PI grants, and 41 NCI grants totaling more than $7M. CCI investigators have had an expanding leadership footprint within the NCI National Clinical Trials Network, and other NCI-supported consortia including MPN Research Consortium, BMT-CTN, Alliance, Mount Sinai Acute GVHD Consortium, AIDS Malignancy Consortium. Investigators have led Phase 3 trials leading to the approval of nivolumab for bladder cancer, discovered Parkinsonism as novel side-effect of BCMA CART in Myeloma and developed BET inhibitors as novel therapies for MPN. A deeper understanding of immune microenvironment by our world class immunology program has led to trials using anti-IL-4 therapy for lung cancer, and insights into NASH and hepatocellular cancer. Through engagement with the Center for Outreach, CCI investigators are involved in several funded projects to improve access to care. CCI members are actively engaged in the pipeline of training programs to mentor cancer clinical and translational students, including high school and undergraduates, pre-doctoral and postdoctoral physician scientists, and junior faculty. To further build on our foundation to evolve treatment science, we plan to submit multiple multi-PI multi-project grants in the next cycle, and continue to catalyze first in human research, translational science, outreach and education.